Marker Therapeutics

TapImmune, Inc. (NASDAQ: TPIV) will pursue a new approach to treating cancer through a proposed merger with privately held Marker Therapeutics, a WBB Securities analyst said in an upgrade note.  The Analyst  WBB Securities analyst Steve Brozak upgraded TapImmune from a Speculative Buy...